COMDTINST 6570.2A
1 DEC 1993
Due to reassignments and career progression, Coast Guard beneficiaries can expect to receive
health care from many Coast Guard and DOD facilities during their military career.
5.
DISCUSSION. With a mobile patient and health care provider population, the advantages of
drug product standardization are obvious. The use of Coast Guard Core Formulary
medications whenever possible, ensures that the products required by our patients are readily
available when they relocate. The core formulary also allows health care providers, at all
levels, to provide care immediately upon arrival at their new assignment. Otherwise,
formulary revisions and required procurement times for new drugs result in both delay in
patient care and possible waste of eliminated formulary items.
6.
RESPONSIBILITIES. Frequent therapeutic advances and the multitude of drug products
available make it difficult and time-consuming for each clinic to maintain and continually
research information about the entire scope of this formulary. For these reasons,
responsibilities for drug therapeutic categories will be divided among Coast Guard pharmacy
officers. This will prevent duplication of effort by each Coast Guard clinic and save time for
pharmacy officers. Under MLC guidance, collateral duty pharmacy officers shall work with
independent duty HSs to ensure that all Coast Guard active duty members and their
dependents receive pharmaceutical services in a cost-effective manner.
a.
Commandant (G-KOM) will:
(1)
Review and revise the Core Formulary annually or as necessary using input from
Coast Guard units. Medical Logistics Messages may be used to make immediate
changes.
(2)
Assign specific therapeutic category responsibilities to Coast Guard pharmacy
officers.
b.
Commanders (k), Maintenance and Logistics Commands shall:
(1)
Monitor the degree of compliance with the Core Formulary during QA site visits.
QA Site Visit reports to Commandant (G-KOM) shall include a list of those non-
core formulary items which the clinic maintains on its formulary and the list of
special order items and the number of patients for which they are being procured.
(2)
Consider the degree of compliance with this instruction when reviewing annual
and supplemental budget requests via the budget process.
(3)
Direct reviewers of nonfederal invoice and blanket purchase agreements to refer
the patient identities and medication name(s) for chronically used pharmaceuticals
to the MLC pharmacy officer.
2
Previous Page
